CompletedNCT04754750
Monthly and three-month paliperidone treatment and cognition in schizophrenia
About this title
Read the official source — NCT04754750Medication studyAges 30–69
Understand this study
Who was this study for?
Listed age limits: 30 years to 69 years.
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateStarted: January 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- 72
- Sponsor
- Calo Psychiatric Center
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- Not clearly listed
- Age range
- From 30 Years to 69 Years
- Official registry ID
- NCT04754750
- Official title
Show the full official title
Differences in Lipid and Cognitive Change Between One-month and 3-month Paliperidone Palmitate Treatment in Stable Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Locations not listed
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Calo Psychiatric Center.
Did this study involve medication?
Yes. The study involved medication, including Paliperidone Palmitate 156 MG/ML Prefilled Syringe [Invega] and Paliperidone Palmitate 546 MG Intramuscular Suspension, Extended Release [INVEGA TRINZA].
Who was this study for?
Listed age limits: 30 years to 69 years.
